Originally published as JCO Early Release 10.1200/JCO.2002.04.084 on July 1 2002

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pentz, R. D. Articles by Abbruzzese, J. L. Search for Related Content PubMed PubMed Citation Articles by Pentz, R. D. Articles by Abbruzzese, J. L.

Study of the Media’s Potential Influence on Prospective Research Participants’ Understanding of and Motivations for Participation in a High-Profile Phase I Trial

From the University of Texas M.D. Anderson Cancer Center, Houston, TX; Winship Cancer Institute, Emory University, Atlanta, GA; and Duke University, Durham, NC.

Address reprint requests to Rebecca D. Pentz, PhD, Winship Cancer Institute, Emory University, 1365 B Clifton Rd NE Suite 6200, Atlanta, GA 30322; email: rebecca_pentz{at}emoryhealthcare.org

PURPOSE: To describe prospective participants’ initial source of information about, understanding of, and motivation to participate in a phase I clinical trial of the antiangiogenesis agent human recombinant endostatin.

PATIENTS AND METHODS: We surveyed 100 of 130 persons referred to the endostatin trial between October 1999 and November 2000 and analyzed media coverage of the agent from 1997 to 2000.

RESULTS: Forty-seven percent of survey respondents first heard about the trial from media reports. Fifty-one percent of these subsequently contacted their physicians. Thirty-three percent of respondents correctly understood the purpose of the trial. Seventy-nine respondents were interviewed before they met trial investigators to discuss the trial. Of these, those who first heard about endostatin from the media were five times more likely to understand correctly the trial’s purpose than those who first heard from other sources. Seventy-four percent (70 of 95) of respondents cited hope for personal benefit as the main reason for their willingness to enroll. Those who first heard about endostatin from the media were no more motivated by hope of personal benefit (77%) than those who first heard from other sources (71%) (P = .46). Ninety-nine percent of all respondents cited "joining the study gives me hope" as a contributing factor in their decision making about the trial.

CONCLUSION: Media coverage prompted prospective participants to contact their physicians but did not seem to hinder understanding nor could it be shown to heighten their hope for personal benefit.

This article has been cited by other articles:

				J. Seidenfeld, E. Horstmann, E. J. Emanuel, and C. Grady Participants in Phase 1 Oncology Research Trials: Are They Vulnerable? Arch Intern Med, January 14, 2008; 168(1): 16 - 20. [Abstract] [Full Text] [PDF]

				S. L. Berg Ethical Challenges in Cancer Research in Children Oncologist, November 1, 2007; 12(11): 1336 - 1343. [Abstract] [Full Text] [PDF]

				W Glannon Phase I oncology trials: why the therapeutic misconception will not go away J. Med. Ethics, May 1, 2006; 32(5): 252 - 255. [Full Text] [PDF]

				J. H. M. Schellens and M. J. Ratain Endostatin: Are the 2 Years Up Yet? J. Clin. Oncol., September 15, 2002; 20(18): 3758 - 3760. [Full Text] [PDF]

				C. K. Daugherty The "Cure" for Cancer: Can the Media Report the Hope Without the Hype? J. Clin. Oncol., September 15, 2002; 20(18): 3761 - 3764. [Full Text] [PDF]

				R. S. Herbst, K. R. Hess, H. T. Tran, J. E. Tseng, N. A. Mullani, C. Charnsangavej, T. Madden, D. W. Davis, D. J. McConkey, M. S. O'Reilly, et al. Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors J. Clin. Oncol., September 15, 2002; 20(18): 3792 - 3803. [Abstract] [Full Text] [PDF]